The use of indometacin for treating diffuse glomerulonephritis under experimental and clinical conditions.
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy; D001796:Blood Protein Disorders / Q000188:drug therapy; D001798:Blood Proteins / Q000032:analysis; D003168:Complement Fixation Tests; D004353:Drug Evaluation, Preclinical; D005620:Freund's Adjuvant; D005919:Glomerular Filtration Rate; D005921:Glomerulonephritis / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D006973:Hypertension / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007213:Indomethacin / Q000009:adverse effects / Q000627:therapeutic use*; D007267:Injections; D007672:Kidney Cortex; D008297:Male; D011507:Proteinuria / Q000188:drug therapy; D051381:Rats; D012712:Serum Globulins / Q000032:analysis; D013270:Stomach / Q000187:drug effects; D014511:Uremia / Q000188:drug therapy
D001798:Blood Proteins; D007166:Immunosuppressive Agents; D012712:Serum Globulins; D005620:Freund's Adjuvant; D007213:Indomethacin